Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib
- 16 August 2018
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 27 (3) , 1029-1039
Abstract
Afatinib is a standard first-line therapy for advanced EGFR-positive NSCLC. We implemented a pharmacist-led proactive follow-up algorithm to identify and manage early afatinib-related adverse events (AEs).Keywords
Funding Information
- Boehringer Ingelheim
This publication has 33 references indexed in Scilit:
- Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network, 2017
- The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysisOncotarget, 2016
- Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2015
- Cancer statistics, 2014CA: A Cancer Journal for Clinicians, 2014
- Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)Journal of Clinical Oncology, 2013
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialThe Lancet Oncology, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21Journal of Clinical Oncology, 2008
- Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, ErlotinibCancer Research, 2006
- Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung CancersJNCI: Journal of the National Cancer Institute, 2005